Personalized therapy for pazopanib

Personalized therapy for pazopanib - Personalized therapy for pazopanib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021999

Enrollment

Registered

2016-04-20

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant soft tissue tumor Renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving pazopanib for malignant soft tissue tumor or renal cell carcinoma

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
To compare blood concentration, efficy and adverse events of pazopanib	—

Secondary

Measure	Time frame
To evaluate factors that affect the blood concentration of pazopanib	—

Countries

Japan

Contacts

Public ContactHiroaki Yamaguchi

Tohoku university hospital Department of pharmaceutical sciences

yamaguchi@hosp.tohoku.ac.jp022-717-7528

Outcome results